ReviewFrontiers in endocrinology2021
Muscle-Bone Crosstalk in Chronic Obstructive Pulmonary Disease.
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The impact of sarcopenia on the incidence of postoperative outcomes following spine surgery: Systematic review and meta-analysis.PloS one · 2024Pooled it
- Review
- Integration of patient-reported outcomes and myokine profiling for the detection of physical inactivity in COPD: an exploratory multicentre study.Scientific reports · 2026Article
- Exploring neuronal mechanisms of osteosarcopenia in older adults.The Journal of physiology · 2026Review
- The lung-muscle axis in COPD: a conceptual framework integrating evidence, mechanisms, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Coexisting Sarcopenia and Osteoporosis in COPD: Integrated Identification, Risk-Oriented Assessment, and Comprehensive Management-A Structured Narrative Review.International journal of chronic obstructive pulmonary disease · 2026Review
- Muscle Wasting and Treatment of Dyslipidemia in COPD: Implications for Patient Management.Biomedicines · 2025Review
- Prognostic impact of osteosarcopenia on postoperative outcomes in patients with biliary tract cancer.Surgery today · 2025Article
- Bone-muscle interactions.Osteoporosis and sarcopenia · 2025Review
- Skeletal Muscle Function in Relation to COPD Severity and Its Predictive Significance for Disease Progression.International journal of chronic obstructive pulmonary disease · 2025Article
- Crosstalk between muscle and bone.Journal of bone and mineral metabolism · 2024Review
- Mechanisms of osteoporosis associated with chronic obstructive pulmonary disease.Journal of bone and mineral metabolism · 2024Review
- Unveiling the Knowledge Frontier: A Scientometric Analysis of COPD with Sarcopenia.International journal of chronic obstructive pulmonary disease · 2024Article
- Managing Osteoporosis in COPD.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Inflammatory Processes Affecting Bone Health and Repair.Current osteoporosis reports · 2023Review
- Prognostic significance of osteosarcopenia in older adults with colorectal cancer.Annals of gastroenterological surgery · 2023Article
- Chronic airway disease as a major risk factor for fractures in osteopenic women: Nationwide cohort study.Frontiers in endocrinology · 2023Article
- The Importance of the Diaphragm in Neuromotor Function in the Patient with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Review
- Article
- Role of nutrition in patients with coexisting chronic obstructive pulmonary disease and sarcopenia.Frontiers in nutrition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia and osteoporosis are common musculoskeletal comorbidities of chronic obstructive pulmonary disease (COPD) that seriously affect the quality of life and prognosis of the patient. In addition to spatially mechanical interactions, muscle and bone can also serve as endocrine organs by producing myokines and osteokines to regulate muscle and bone functions, respectively. As positive and negative regulators of skeletal muscles, the myokines irisin and myostatin not only promote/inhibit the differentiation and growth of skeletal muscles, but also regulate bone metabolism. Both irisin and myostatin have been shown to be dysregulated and associated with exercise and skeletal muscle dysfunction in COPD. During exercise, skeletal muscles produce a large amount of IL-6 which acts as a myokine, exerting at least two different conflicting functions depending on physiological or pathological conditions. Remarkably, IL-6 is highly expressed in COPD, and considered to be a biomarker of systemic inflammation, which is associated with both sarcopenia and bone loss. For osteokines, receptor activator of nuclear factor kappa-B ligand (RANKL), a classical regulator of bone metabolism, was recently found to play a critical role in skeletal muscle atrophy induced by chronic cigarette smoke (CS) exposure. In this focused review, we described evidence for myokines and osteokines in the pathogenesis of skeletal muscle dysfunction/sarcopenia and osteoporosis in COPD, and proposed muscle-bone crosstalk as an important mechanism underlying the coexistence of muscle and bone diseases in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.